ICU Medical (NASDAQ:ICUI) Rating Lowered to Hold at Zacks Research

ICU Medical (NASDAQ:ICUI) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. BTIG Research began coverage on ICU Medical in a research report on Monday, June 15th. They set a “buy” rating and a $170.00 price target on the stock. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Piper Sandler cut their target price on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Sanford C. Bernstein lowered ICU Medical to a “market perform” rating in a report on Monday, June 15th. Finally, Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $172.00.

ICU Medical Stock Performance

NASDAQ ICUI opened at $166.53 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $4.16 billion, a P/E ratio of 90.02, a P/E/G ratio of 2.32 and a beta of 0.76. ICU Medical has a 12-month low of $107.00 and a 12-month high of $170.48. The firm has a 50-day moving average price of $146.57 and a two-hundred day moving average price of $140.00.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping the consensus estimate of $1.78 by $0.19. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. During the same period last year, the firm earned $1.72 earnings per share. The business’s revenue for the quarter was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Analysts anticipate that ICU Medical will post 6.51 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In other news, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the transaction, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ICU Medical

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of ICU Medical by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock valued at $387,313,000 after purchasing an additional 89,755 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of ICU Medical by 3.9% in the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock valued at $345,607,000 after buying an additional 99,256 shares during the period. Millennium Management LLC raised its holdings in ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in ICU Medical by 6.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock valued at $127,053,000 after buying an additional 63,026 shares during the last quarter. Finally, State Street Corp boosted its position in ICU Medical by 2.8% during the 4th quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier’s stock worth $134,491,000 after buying an additional 25,545 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.